Heart Failure clinical trial intelligence

The Effects of Neprilysin on Glucagon-like Peptide-1

The Effects of Neprilysin on Glucagon-like Peptide-1 is a PHASE4 clinical asset sponsored by Nicolai Jacob Wewer Albrechtsen in Diabetes, Heart Failure. SEO and diligence focus: Entresto, Sitagliptin 100mg, Placebos, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Heart Failure

Treatment With Glucagon-Like Peptide-1 Receptor, Exenatide, in Patients With Diabetes and Heart Failure With Normal Left Ventricular Ejection Fraction

The study aimed to evaluate the effects of exenatide, a GLP-1 receptor agonist, on heart failure in patients with type 2 diabetes. Despite the potential market for diabetes medications that also address cardiovascular complications, the trial was terminated due to inadequate recruitment. This indicates challenges in patient enrollment for studies targeting specific comorbidities, which may affect future clinical development strategies. The competitive landscape includes other GLP-1 receptor agonists and heart failure treatments, necessitating a focus on differentiated clinical benefits to capture market share.

Matched by conditions: Heart Failure, Diastolic

The Effects of SGLT Inhibition on Diabetic Cardiomyopathy

The clinical trial, sponsored by The University of Hong Kong, investigates the effects of SGLT2 inhibition on diabetic cardiomyopathy, a condition with significant morbidity and mortality among patients with type 2 diabetes. The study aims to elucidate the mechanistic insights of dapagliflozin, an SGLT2 inhibitor, on cardiovascular outcomes beyond glycemic control. Given the increasing prevalence of diabetes and associated cardiovascular complications, successful outcomes could enhance dapagliflozin's market positioning against competitors in the SGLT2 inhibitor space, such as empagliflozin and canagliflozin. The findings may also support expanded indications for SGLT2 inhibitors, potentially leading to new revenue streams and increased market share. Investors should monitor the trial's progress and results for implications on market dynamics and competitive landscape.

Matched by conditions: Heart Failure With Reduced Ejection Fraction

Evaluation of a Pragmatic NT-ProBNP-based Heart Failure Screening Strategy Among Patients With Type 2 Diabetes: STRONG-DM Study (Screening and Treatment Using Risk-based apprOach With NT-ProBNP Guidance in Diabetes Mellitus

The STRONG-DM study, sponsored by the University of Texas Southwestern Medical Center, aims to evaluate a pragmatic heart failure screening strategy utilizing NT-proBNP and clinical risk scores among patients with Type 2 Diabetes. This study is particularly relevant given the increasing prevalence of diabetes and associated cardiovascular complications, representing a significant market opportunity for preventive therapies such as SGLT2 inhibitors and GLP-1 agonists. The collaboration with Roche Diagnostics indicates potential for leveraging diagnostic capabilities, which could enhance the commercial viability of the intervention. The outcomes may influence clinical guidelines and reimbursement strategies, impacting market dynamics for heart failure management in diabetic patients.